Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 10/20 | 0.69 |
| ▸ | RAB9A | P51151 | 10/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.69 |
| ▸ | TP53 | P04637 | 3/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | FGFR1 | P11362 | 7/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23680588 | 0.82 | HPGD (0.62) | TP53HPGDALDH1A1FGFR1 | |
| SCHEMBL7989436 | 0.81 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2TP53LMNA | |
| Hydrochloric Acid SCHEMBL7976246 | 0.80 | NPC1 (0.97) | NPC1RAB9ASMN1; SMN2TP53LMNA | |
| SCHEMBL7987076 | 0.78 | RAB9A (1.00) | NPC1RAB9ASMN1; SMN2TP53LMNA | |
| SCHEMBL7986579 | 0.78 | RAB9A (0.71) | NPC1RAB9ASMN1; SMN2TP53LMNA | |
| SCHEMBL6756590 | 0.77 | FGFR1 (1.00) | ALDH1A1FGFR1 | |
| Hydrochloric Acid SCHEMBL7990425 | 0.77 | RAB9A (0.98) | NPC1RAB9ASMN1; SMN2TP53LMNA | |
| SCHEMBL7989417 | 0.77 | FGFR1 (1.00) | NPC1RAB9ASMN1; SMN2LMNAHPGD | |
| SCHEMBL17531409 | 0.77 | FGFR1 (0.57) | NPC1RAB9ASMN1; SMN2TP53LMNA | |
| SCHEMBL30343716 | 0.76 | FGFR1 (1.00) | NPC1RAB9ALMNAHPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210220408-A1 | ARYL HYDROCARBON RECEPTOR ANTAGONISTS AND METHODS OF USE | EDIGENE BIOTECHNOLOGY, INC. (CN) | 2021-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210220408-A1 | ARYL HYDROCARBON RECEPTOR ANTAGONISTS AND METHODS OF USE | AHR, ARNT, ARSA | NPC1 1022/4885RAB9A 4056/4885SMN1; SMN2 3198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.